10 Best Low Priced Growth Stocks To Invest In

7. Roivant Sciences Ltd. (NASDAQ:ROIV)

Revenue CAGR last 5 years: 29.37%

Stock price as of April 7th close: $9.26

Number of Hedge Fund Holders: 44

​Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company that develops innovative medicines and technologies in such therapeutic areas as oncology, immunology, hematology, and dermatology. ROIV has some notable product candidates for dermatomyositis and non-infectious uveitis, and inflammatory disorders like sarcoidosis. The company has formed strategic partnerships with other major biotech firms like Pfizer and Roche to further boost its R&D and accelerate innovation.

Roivant Sciences Ltd. (NASDAQ:ROIV) entered calendar 2025 with several significant milestones ahead, including imminent data readouts and a registrational readout in dermatomyositis expected mid-year that could set the stage for the commercial launch of “brepocitinib”, a promising medicine. The company maintains a strong financial position with $5.2 billion in cash and marketable securities as of 2024 end, which makes it well-positioned to withstand any short-term slowdown in demand as well as rapidly allocate capital if new opportunities arise.

Roivant Sciences Ltd. (NASDAQ:ROIV) is expanding its pipeline with new initiatives, including a proof-of-concept study for “brepocitinib” in cutaneous sarcoidosis, targeting 30,000 to 50,000 patients with no approved therapies. Additionally, Immunovant’s development program is advancing rapidly, positioning the company for potential multi-blockbuster launches. The company also anticipates significant developments in its litigation against Moderna and Pfizer/BioNTech, with a jury trial scheduled for September and a summary judgment phase in the second to third quarter of 2025. We include ROIV in 7th place on our list of best low priced stocks as we believe it has substantial potential upside from its current R&D pipeline.